How to buy Vertex Pharmaceuticals (VRTX) stock from India

Yes, an Indian resident can buy Vertex — legally, in US dollars, under the RBI's Liberalised Remittance Scheme (LRS). The buying is the easy 10%. The 90% that decides your outcome is tax, estate-tax exposure, and position sizing. VRTX has one helpful quirk: it pays no dividend, so US withholding and Form 67 are a non-issue. This is the short version.

The 30-second version

• Legal and simple. Buy VRTX via any India-facing platform (Vested, INDmoney) or a global broker (Interactive Brokers, Rovia). Whole shares or a fractional rupee amount.
• Pure capital-gains play. VRTX has never paid a dividend and reinvests cash into R&D and buybacks, so US dividend withholding and Form 67 are essentially irrelevant.
• India tax: hold more than 24 months and pay 12.5% LTCG (no indexation); sell sooner and pay your slab rate. This is Section 112, not the friendlier 112A that Indian shares get.
• The trap most miss: directly-held VRTX is a US-situs asset — above $60,000, your estate faces up to 40% US estate tax, with no India-US treaty relief.
• If your thesis is "US biotech," IBB or XBI already hold VRTX as a top weight — same exposure, no single-stock risk.

Quick facts

Can an Indian resident buy it?	Yes — fully legal under the LRS
Ticker / exchange	VRTX / Nasdaq
How	India-facing platform (Vested, INDmoney) or global broker (IBKR, Rovia)
Minimum	A fraction of one share (matters here — VRTX trades in the mid-hundreds)
Dividend	None — VRTX has never paid one and reinvests cash into R&D and buybacks
India tax on gains	12.5% LTCG after 24 months; else your slab (Section 112)
Estate-tax risk	US-situs above $60k means up to 40%, no treaty relief
Annual compliance	Schedule FA disclosure, every year you hold

How to buy it — 3 steps

1. Open an account and finish KYC. Pick an India-facing platform (Vested, INDmoney) for a simple India-funded experience, or a global broker (Interactive Brokers, Rovia) for wider access. File your W-8BEN during onboarding — still good practice even with no current dividend, because it covers any future distribution. New here? Start with how to invest in US stocks from India.
2. Fund it via the LRS. Remit from your Indian bank under the LRS (cap: $250,000 per financial year). 20% TCS applies above ten lakh rupees in a year — a creditable prepayment, not a cost. See LRS explained and the LRS and TCS calculator.
3. Place the order. VRTX is a high-priced share — typically in the $400-$520 range — so one whole share is a meaningful rupee outlay. Fractional shares let you size the position precisely.

The tax that actually matters

Vertex pays no dividend, so the 25% US withholding and annual Form 67 foreign-tax-credit dance — a recurring headache with names like Microsoft or Apple — does not apply. Your entire tax exposure is on capital gains when you sell, under Section 112 (foreign shares don't get the Section 112A treatment Indian equity enjoys):

Holding period	Treatment	Rate
24 months or less	Short-term	Your slab rate (up to roughly 30% plus surcharge)
More than 24 months	Long-term	12.5%, no indexation

Worked example. Buy 3 shares at $420 when USD/INR is 86 → cost 1,08,360 rupees. Sell 28 months later at $510 when USD/INR is 88 → proceeds 1,34,640 rupees. Taxable gain 26,280 rupees; LTCG at 12.5% = 3,285 rupees. A weaker rupee at sale amplifies the rupee gain — gains are computed in rupees, not dollars. At VRTX's price, fractional shares matter: a 1-share position is already roughly forty thousand rupees. Model your own with the US capital-gains calculator; full rules in how US stocks are taxed in India. For Form 67 context (relevant if you hold dividend-paying US names), see dividend withholding and Form 67.

The $60,000 estate-tax trap

Directly-held VRTX is a US-situs asset. If the holder dies with more than $60,000 of US-situs assets, the estate faces US estate tax up to 40% — and the India-US treaty does not cover estate tax, so no credit or relief. The fix (holding through pooled or fund structures) has to be a deliberate choice made before the position gets large. Full detail: the $60,000 estate-tax trap.

Buy the stock, or get Vertex through an ETF?

If you want…	Best route
A concentrated bet that VRTX leads large-cap biotech	VRTX directly
"US biotech / innovation pharma will keep winning" exposure	IBB or XBI — VRTX is a top weight, plus dozens of other biotech names
Broad US-market exposure that happens to include VRTX	VOO, VTI, or QQQ — VRTX sits inside the index, but at a small weight
Zero dividend-tax paperwork on the position	VRTX works either way — it pays nothing
The least single-stock risk	A broad ETF

VRTX sits in VOO, VTI and QQQ as one of several hundred holdings — only modest exposure. The biotech ETFs — IBB (large-cap biotech, market-cap weighted) and XBI (equal-weighted) — give a much heavier VRTX weight alongside dozens of other biotech names, one Schedule FA entry, and cleaner estate-tax treatment via pooled vehicles. Compare in direct stocks vs US ETFs and best US ETFs for Indian investors; broader case in US ETFs for Indians.

The business in one screen

What it is: Vertex runs the world's only meaningful cystic fibrosis (CF) franchise — Trikafta/Kaftrio plus next-generation Alyftrek (vanza triple) — covering roughly 90% of CF patients, patent-protected into the 2030s with no biosimilar threat. CF cash flow funds a pipeline finally diversifying: Journavx (suzetrigine, a non-opioid acute-pain drug FDA-approved early 2025), Casgevy (first approved CRISPR gene therapy, partnered with CRISPR Therapeutics, for sickle cell and beta thalassemia), inaxaplin for APOL1 kidney disease, and povetacicept for IgA nephropathy.

Bull case	Bear case
CF franchise is a near-monopoly, patent-protected into the 2030s	CF is roughly 90% of revenue — one-category concentration risk
Journavx (suzetrigine) launching into a non-opioid pain TAM north of $20B	Suzetrigine launch execution, payer access and pricing still unproven
Casgevy is the first-in-class CRISPR gene therapy with growing access	Gene-therapy pricing and reimbursement pushback in the US and EU
Deep late-stage pipeline in kidney disease and autoimmune	FDA/regulatory risk on inaxaplin, povetacicept and other late-stage assets
Strong free cash flow, large net cash, disciplined capital allocation	Premium valuation leaves limited margin for any execution slip

Exact valuation is in the widget above — the highest-quality biotech franchise outside Big Pharma, priced for continued execution.

Our take

Verdict: BUY — best-quality biotech franchise outside Big Pharma, clean tax profile (no dividend), real pipeline optionality on top of monopoly-grade CF cash flow.

• Monopoly-grade base business. Trikafta plus Alyftrek is structurally unlike most pharma cash cows: no second player of consequence, no biosimilar pathway, patents into the 2030s. A multi-year runway of high-margin revenue funds everything else.
• Real pipeline diversification, not just slides. Journavx for non-opioid acute pain (approved early 2025), Casgevy in sickle cell and beta thalassemia, inaxaplin in APOL1 kidney disease, and povetacicept in IgA nephropathy are four distinct shots on goal. Base case: CF plus one working; upside stacks more on top.
• Unusually clean tax profile. No dividend means no 25% US withholding, no Form 67, no double-tax friction — just a pure Section 112 decision when you sell. Fits as a high-conviction satellite for an Indian investor wanting biotech exposure without recurring tax admin.

Compliance note. Vested.blog is not a SEBI-registered Research Analyst. The above is an editorial opinion for educational illustration only — not investment advice and not a regulated stock recommendation. Vested.blog is published by Rovia; the publisher and its affiliates may hold positions in stocks discussed. Make your own decisions or consult a SEBI-registered advisor.

Risks to size for

• CF concentration. Roughly 90% of revenue still comes from one category. Any payer pushback, label change, or competitive entry in CF would hit Vertex disproportionately. Diversification is real but will take years to shift the mix.
• Launch execution on suzetrigine and Casgevy. Journavx targets a huge non-opioid pain market, but uptake depends on payer formularies, pricing, and physician adoption. Casgevy faces the reimbursement and logistics challenges slowing other gene therapies.
• Currency: your return is in USD but you spend rupees — see the rupee-dollar effect.

Two things people forget

• Schedule FA: disclose VRTX in Schedule FA of your ITR every year you hold it — even if bought and sold within the year, even at a loss. Non-disclosure carries Black Money Act penalties. No dividend means you skip Form 67 — but Schedule FA is non-negotiable. Use the Schedule FA helper.
• Position size: a single biotech, however dominant, is not an index. Size VRTX as a high-conviction satellite, not a substitute for a broad ETF — the high share price means small share counts add up to meaningful rupee positions quickly.

Bottom line

Buying VRTX from India is easy and legal. What needs thought isn't the buying — it's that VRTX is a Section-112 capital-gains play (12.5% after 24 months), a US-situs asset with a $60k estate-tax trap, and a single biotech needing disciplined position sizing despite the franchise quality. The upside versus most large-cap pharma: no dividend means no recurring 25% withholding and no Form 67 work. If your thesis is "US biotech innovation," IBB or XBI gives the exposure without the concentration. For accounts and options, start at the US investing hub.

---

This article is general information, not personalised investment, tax, or legal advice. Rules, rates, and thresholds described here are as of 2026 and can change; verify the current position and consult a qualified advisor before acting.